LivaNova Sleep Apnea Device Could Drive Growth From 2026, Needham Says

MT Newswires Live

2025/09/04

LivaNova (LIVN) could see growth contributions starting in 2026 from its aura6000 hypoglossal nerve stimulation device for obstructive sleep apnea, Needham said in a Wednesday note.

The firm said LivaNova submitted the device for premarket approval and estimated potential FDA clearance in the first half of 2026. In its base-case scenario, Needham projects aura6000 could add 2.2% to annual revenue growth and 4.7% to annual earnings per share growth from 2026 to 2029.

The brokerage highlighted results from the osprey trial, which showed a 65% responder rate and a 68% reduction in apnea-hypopnea index at 12 months. The firm said LivaNova expects to launch the device after obtaining MRI compatibility approval, likely in late 2026.

The device could capture market share from Inspire Medical (INSP), with advantages including longer battery life, the ability to treat patients with complete concentric collapse, and no requirement for a drug-induced sleep endoscopy procedure.

Needham has a buy rating and a $64 price target on LivaNova.

Shares of LivaNova were down 1.4% in recent trading.

Price: 56.10, Change: -0.82, Percent Change: -1.44

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2564169023"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564169023\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564169023?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 03:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564169023","market":"fut","top_or_hot":-1,"title":"LivaNova Sleep Apnea Device Could Drive Growth From 2026, Needham Says","media":"MT Newswires Live","content":"<html><body><p> LivaNova (LIVN) could see growth contributions starting in 2026 from its aura6000 hypoglossal nerve stimulation device for obstructive sleep apnea, Needham said in a Wednesday note.</p><p>The firm said LivaNova submitted the device for premarket approval and estimated potential FDA clearance in the first half of 2026. In its base-case scenario, Needham projects aura6000 could add 2.2% to annual revenue growth and 4.7% to annual earnings per share growth from 2026 to 2029.</p><p>The brokerage highlighted results from the osprey trial, which showed a 65% responder rate and a 68% reduction in apnea-hypopnea index at 12 months. The firm said LivaNova expects to launch the device after obtaining MRI compatibility approval, likely in late 2026.</p><p>The device could capture market share from Inspire Medical (INSP), with advantages including longer battery life, the ability to treat patients with complete concentric collapse, and no requirement for a drug-induced sleep endoscopy procedure.</p><p>Needham has a buy rating and a $64 price target on LivaNova.</p><p>Shares of LivaNova were down 1.4% in recent trading.</p><p>Price: 56.10, Change: -0.82, Percent Change: -1.44</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LivaNova Sleep Apnea Device Could Drive Growth From 2026, Needham Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLivaNova Sleep Apnea Device Could Drive Growth From 2026, Needham Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-04 03:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> LivaNova (LIVN) could see growth contributions starting in 2026 from its aura6000 hypoglossal nerve stimulation device for obstructive sleep apnea, Needham said in a Wednesday note.</p><p>The firm said LivaNova submitted the device for premarket approval and estimated potential FDA clearance in the first half of 2026. In its base-case scenario, Needham projects aura6000 could add 2.2% to annual revenue growth and 4.7% to annual earnings per share growth from 2026 to 2029.</p><p>The brokerage highlighted results from the osprey trial, which showed a 65% responder rate and a 68% reduction in apnea-hypopnea index at 12 months. The firm said LivaNova expects to launch the device after obtaining MRI compatibility approval, likely in late 2026.</p><p>The device could capture market share from Inspire Medical (INSP), with advantages including longer battery life, the ability to treat patients with complete concentric collapse, and no requirement for a drug-induced sleep endoscopy procedure.</p><p>Needham has a buy rating and a $64 price target on LivaNova.</p><p>Shares of LivaNova were down 1.4% in recent trading.</p><p>Price: 56.10, Change: -0.82, Percent Change: -1.44</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065731478.USD","symbol_name":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2564169023","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564169023","pubTimestamp":1756928654,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"LivaNova  could see growth contributions starting in 2026 from its aura6000 hypoglossal nerve stimulation device for obstructive sleep apnea, Needham said in a Wednesday note.The firm said LivaNova submitted the device for premarket approval and estimated potential FDA clearance in the first half of 2026. In its base-case scenario, Needham projects aura6000 could add 2.2% to annual revenue growth and 4.7% to annual earnings per share growth from 2026 to 2029.The brokerage highlighted results from the osprey trial, which showed a 65% responder rate and a 68% reduction in apnea-hypopnea index at 12 months. The firm said LivaNova expects to launch the device after obtaining MRI compatibility approval, likely in late 2026.The device could capture market share from Inspire Medical , with advantages including longer battery life, the ability to treat patients with complete concentric collapse, and no requirement for a drug-induced sleep endoscopy procedure.Needham has a buy rating and a $64 ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LIVN":"LivaNova PLC","INSP":"Inspire Medical Systems","BK4167":"医疗保健技术","BK4082":"医疗保健设备"},"translate_title":"Needham表示，LivaNova睡眠呼吸暂停设备可能会从2026年起推动增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSP":0.9,"LIVN":0.9},"content_text":"LivaNova (LIVN) could see growth contributions starting in 2026 from its aura6000 hypoglossal nerve stimulation device for obstructive sleep apnea, Needham said in a Wednesday note.The firm said LivaNova submitted the device for premarket approval and estimated potential FDA clearance in the first half of 2026. In its base-case scenario, Needham projects aura6000 could add 2.2% to annual revenue growth and 4.7% to annual earnings per share growth from 2026 to 2029.The brokerage highlighted results from the osprey trial, which showed a 65% responder rate and a 68% reduction in apnea-hypopnea index at 12 months. The firm said LivaNova expects to launch the device after obtaining MRI compatibility approval, likely in late 2026.The device could capture market share from Inspire Medical (INSP), with advantages including longer battery life, the ability to treat patients with complete concentric collapse, and no requirement for a drug-induced sleep endoscopy procedure.Needham has a buy rating and a $64 price target on LivaNova.Shares of LivaNova were down 1.4% in recent trading.Price: 56.10, Change: -0.82, Percent Change: -1.44","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}